Child responding to Chimerix's brincidofovir

Josh Hardy has experienced a dramatic reduction in viral load since receiving brincidofovir ( CMX001) from Chimerix Inc. (NASDAQ:CMRX), his mother Aimee Hardy told BioCentury Wednesday. Josh Hardy is the first patient in an open-label pilot trial to treat adenovirus infections in immunocompromised patients. Following two doses given on March 12 and 15, his viral load has dropped from 250,000 copies of adenovirus per mL to 1,000 copies, she reported. "He's having some other challenges not related to adenovirus that hopefully will be resolved soon. We expect him to be moved out of the ICU this week or next week," she said. ...